Nateglinide
 |
|
| Clinical data | |
|---|---|
| Trade names | Starlix |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a699057 |
| License data |
|
| Routes of administration |
Oral |
| ATC code | A10BX03 (WHO) |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Protein binding | 98% |
| Biological half-life | 1.5 hours |
| Identifiers | |
|
|
| CAS Number | 105816-04-4  |
| PubChem (CID) | 60026 |
| IUPHAR/BPS | 6833 |
| DrugBank | DB00731 |
| ChemSpider | 10482084 |
| UNII | 41X3PWK4O2 |
| KEGG | D01111  |
| ChEBI | CHEBI:31897 |
| ChEMBL | CHEMBL286559 |
| ECHA InfoCard | 100.170.086 |
| Chemical and physical data | |
| Formula | C19H27NO3 |
| Molar mass | 317.423 g/mol |
| 3D model (Jmol) | Interactive image |
|
|
|
|
| (what is this?) (verify) |
|
Nateglinide (INN, trade name Starlix) is a drug for the treatment of type 2 diabetes. Nateglinide was developed by Ajinomoto, a Japanese company and sold by the Swiss pharmaceutical company Novartis.
Nateglinide belongs to the meglitinide class of blood glucose-lowering drugs.
Contents
Pharmacology[edit]
Nateglinide lowers blood glucose by stimulating the release of insulin from the pancreas. It achieves this by closing ATP-dependent potassium channels in the membrane of the β cells. This depolarizes the β cells and causes voltage-gated calcium channels to open. The resulting calcium influx induces fusion of insulin-containing vesicles with the cell membrane, and insulin secretion occurs.
Contraindications[edit]
Nateglinide is contraindicated in patients who:
- have known hypersensitivity to the compound or any ingredient in the formulation.
- are affected with type 1 (namely insulin-dependent) diabetes mellitus.
- are in diabetic ketoacidosis.
Comparisons with other drugs for type 2 diabetes[edit]
A study funded by Novo Nordisk, the U.S. distributor for Repaglinide, compared their product with Nateglinide in "A randomized, parallel-group, open-label, multicenter 16-week clinical trial".[1] They concluded that the two were similar, but "repaglinide monotherapy was significantly more effective than nateglinide monotherapy in reducing HbA1c and FPG values after 16 weeks of therapy."
Dosage[edit]
Nateglinide is delivered in 60 mg & 120 mg tablet form.
See also[edit]
References[edit]
- ^ Rosenstock, Julio Rosenstock; Hassman, David R.; Madder, Robert D.; Brazinsky, Shari A.; Farrell, James; Khutoryansky, Naum; Hale, Paula M. (June 2004), "Repaglinide Versus Nateglinide Monotherapy: A randomized, multicenter study", Diabetes Care, American Diabetes Association, 27 (6): 1265–1270, doi:10.2337/diacare.27.6.1265, retrieved 2014-11-20
External links[edit]
- Starlix - website of the manufacturer.
- How Nateglinide Works - website of the manufacturer.
